SEARCH:   Advanced

Blood, 1 November 2005, Vol. 106, No. 9, pp. 3308-3313. Prepublished online as a Blood First Edition Paper on July 26, 2005; DOI 10.1182/blood-2005-04-1614. This Article Full Text (PDF) All Versions of this Article: 2005-04-1614v1 106/9/3308    most recent Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Pavletic, S. Z Articles by Weisdorf, D. Search for Related Content PubMed PubMed Citation Articles by Pavletic, S. Z Articles by Weisdorf, D. Related Collections Related Article in Blood Online Social Bookmarking                   What's this?  Previous Article  |  Next Article  Submitted April 21, 2005 Accepted June 27, 2005 Influence of T cell depletion on chronic Graft-Versus-Host Disease: results of a multi-center randomized trial in unrelated marrow donor transplantation Steven Z Pavletic*, Shelly L Carter, Nancy A Kernan, Jean Henslee-Downey, Adam M Mendizabal, Esperanza Papadopoulos, Roger Gingrich, James Casper, Saul Yanovich, and Daniel Weisdorf The University of Nebraska Medical Center, Omaha, NE, USA The EMMES Corporation, Rockville, MD, USA Memorial Sloan-Kettering Cancer Center, New York, NY, USA University of South Carolina, Columbia, SC, USA University of Iowa, Iowa City, IA, USA Medical College of Wisconsin, Milwaukee, WI, USA Medical College of Virginia, Richmond, VA, USA University of Minnesota, Minneapolis, MN, USA * Corresponding author; email: pavletis{at}mail.nih.gov. Donor derived T cells have been proposed to play a role in pathogenesis of chronic graft-versus-host disease (cGVHD). The impact of ex vivo T cell depletion (TCD) on cGVHD was analyzed in a randomized multi-center trial involving unrelated donor marrow transplants. 404 patients diagnosed with hematologic malignancies received a total-body irradiation-based myeloablative conditioning regimen. GVHD prophylaxis included TCD plus cyclosporine (CSA) or unmodified grafts with CSA plus methotrexate (M/C). Median recipient age was 31.2 years (range 0.5 - 55.6); median follow up time since randomization was 4.2 yrs. The mean number of T cells infused was 1 log lower on the TCD arm. The incidence of cGVHD at two years was similar between the TCD and M/C arms, 29% vs. 34% (p=0.27), respectively. Survival at three years from diagnosis of cGVHD was also similar, (TCD 51% vs. M/C 58%, p=0.29). The proportion of patients with cGVHD who discontinued immunosuppression at five years was not different (TCD 72% vs. M/C 63%, p=0.27), incidence of serious infections and leukemia relapse were similar on both treatment arms. In spite of significant reduction of acute GVHD, TCD did not reduce the incidence of cGVHD nor improve survival in patients who developed cGVHD. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? Related Article in Blood Online: To T-cell deplete or not Helen E. Heslop Blood 2005 106: 2932. [Full Text] [PDF] This article has been cited by other articles: B. Patel, K. E. Kirkland, R. Szydlo, R. M. Pearce, R. E. Clark, C. Craddock, E. Liakopoulou, A. K. Fielding, S. Mackinnon, E. Olavarria, et al. Favorable outcomes with alemtuzumab-conditioned unrelated donor stem cell transplantation in adults with high-risk Philadelphia chromosome-negative acute lymphoblastic leukemia in first complete remission Haematologica, October 1, 2009; 94(10): 1399 - 1406. [Abstract] [Full Text] [PDF] R. Kapur, S. Ebeling, and A. Hagenbeek B-cell involvement in chronic graft-versus-host disease Haematologica, November 1, 2008; 93(11): 1702 - 1711. [Abstract] [Full Text] [PDF] H. Fujii, G. Cuvelier, K. She, S. Aslanian, H. Shimizu, A. Kariminia, M. Krailo, Z. Chen, R. McMaster, A. Bergman, et al. Biomarkers in newly diagnosed pediatric-extensive chronic graft-versus-host disease: a report from the Children's Oncology Group Blood, March 15, 2008; 111(6): 3276 - 3285. [Abstract] [Full Text] [PDF] S. J. Lee and M. E. D. Flowers Recognizing and Managing Chronic Graft-Versus-Host Disease Hematology, January 1, 2008; 2008(1): 134 - 141. [Abstract] [Full Text] [PDF] Y. Zhang, E. Hexner, D. Frank, and S. G. Emerson CD4+ T Cells Generated De Novo from Donor Hemopoietic Stem Cells Mediate the Evolution from Acute to Chronic Graft-versus-Host Disease J. Immunol., September 1, 2007; 179(5): 3305 - 3314. [Abstract] [Full Text] [PDF] Y. Sakoda, D. Hashimoto, S. Asakura, K. Takeuchi, M. Harada, M. Tanimoto, and T. Teshima Donor-derived thymic-dependent T cells cause chronic graft-versus-host disease Blood, February 15, 2007; 109(4): 1756 - 1764. [Abstract] [Full Text] [PDF] D. Weisdorf GVHD The Nuts and Bolts Hematology, January 1, 2007; 2007(1): 62 - 67. [Abstract] [Full Text] [PDF] C. Cutler, D. Miklos, H. T. Kim, N. Treister, S.-B. Woo, D. Bienfang, L. B. Klickstein, J. Levin, K. Miller, C. Reynolds, et al. Rituximab for steroid-refractory chronic graft-versus-host disease Blood, July 15, 2006; 108(2): 756 - 762. [Abstract] [Full Text] [PDF]

	Copyright © 2005 by American Society of Hematology         Online ISSN: 1528-0020